FY2022 Q3 Financial and R&D Update

Revenue Increased by 137.3 Bn JPY (Increased by 65.0 Bn JPY excl. forex impact) Daiichi-Sankyo Positive Factors (Bn JPY) Negative Factors FY2021 Q3 YTD Results Japan Business 811.0 Japan Business Unit Lixiana +9.1 Nexium (incl. Innovative Pharmaceuticals, 22.2 Tarlige +6.3 Loxonin -39.6 -2.8 Generic, Vaccines, OTC) Gains on sales of products in US +3.5 Oncology Business*1 52.3 Gains on sales of products in EU- +2.6 American Regent 1.2 Oncology Business*1 Unit Enhertu +62.8 Transferred products -7.1 EU Specialty Business 6.8 ASCA American Regent Unit 10.3▸ (Asia, South and Central America) Venofer Enhertu, Dato-DXd*2 HBT products +5.8 +3.3 Injectafer -8.3 16.6 Upfront Payment & Regulatory Milestone Forex Impact*3 FY2022 Q3 YTD Results 72.3 948.3 Positive Factors Negative Factors EU Specialty Business Unit Lixiana +7.2 Gain on sales of transferring long-listed products -1.4 Enhertu, Dato-DXd"² Upfront Payment & Regulatory Milestone Enhertu Regulatory Milestone - +15.7 *1 Revenue for Daiichi Sankyo, Inc. and Daiichi Sankyo Europe's oncology products *2 Dato-DXd: Datopotamab deruxtecan (DS-1062) *3 Forex impact USD: +49.4, EUR: +9.7, ASCA: +13.2 5

View entire presentation